Analytical Data
-
Gene name
CD274
- Application
-
Alternative Names
CD274；B7H1；PDCD1L1；PDCD1LG1；Programmed cell death 1 ligand 1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9NZQ7
-
Expression Region
19-238aa
-
AA Sequence
FTVTVPKDLY VVEYGSNMTI ECKFPVEKQL DLAALIVYWE MEDKNIIQFV HGEEDLKVQH SSYRQRARLL KDQLSLGNAA LQITDVKLQD AGVYRCMISY GGADYKRITV KVNAPYNKIN QRILVVDPVT SEHELTCQAE GYPKAEVIWT SSDHQVLSGK TTTTNSKREE KLFNVTSTLR INTTTNEIFY CTFRRLDPEE NHTAELVIPE LPLAHPPNER
-
Molecular Weight
25 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD274, commonly known as PD-L1, is a protein that plays a critical role in the regulation of immune responses. It is expressed on the surface of various cells, including tumor cells, where it interacts with the PD-1 receptor on T cells to inhibit their activity, facilitating tumor immune evasion. The study of CD274 recombinant protein has gained significant attention in recent years due to its implications in cancer immunotherapy. Researchers have focused on characterizing CD274's structure and function to understand its role in immune modulation and to develop strategies that can block its interaction with PD-1. This blockade can enhance T cell activation and proliferation, thus promoting anti-tumor immunity. Additionally, PD-L1 has emerged as a key biomarker for predicting the efficacy of immunotherapeutic agents, such as monoclonal antibodies that target PD-1 or PD-L1. As a result, recombinant CD274 protein is not only vital for basic research into immune checkpoint mechanisms but also serves as a platform for developing novel therapeutic approaches, including combination therapies that aim to increase the effectiveness of existing cancer treatments. The ongoing research into CD274’s role in immunology continues to provide insights into the tumor microenvironment and opens avenues for potent cancer therapies that harness the body's immune system.
